Avalo Therapeutics Inc (AVTX) Stock Price, Quote & News

Company Profile

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is head...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 522 8707

Website: www.avalotx.com

Address:

1500 Liberty Ridge Drive, Suite 321, Wayne, United States

Trapjaw Sep. 4 at 7:53 PM

$AVTX

0 · Reply

Trapjaw Sep. 2 at 12:39 PM

$AVTX low volume last days. Time for next run to 22

0 · Reply

Quantumup Sep. 1 at 12:10 PM

Chardan on $RCKT said -- We are transferring coverage of Rocket Pharmaceuticals (RCKT) to Keay Nakae, CFA. We maintain our Buy rating and $11 price target. $AVTX $RGNX LXEO TNYA Here's what Chardan went on to say: https://x.com/Quantumup1/status/2094759687719665832?s=20

1 · Reply

FrostyOrbit Aug. 30 at 10:05 PM

$AVTX Cash: $472M, with runway expected into 2029.zz.

0 · Reply

Trapjaw Aug. 26 at 8:01 PM

$AVTX no sell off

0 · Reply

CaptainCoin3 Aug. 26 at 6:35 PM

$AVTX get ready for takeoff

0 · Reply

Trapjaw Aug. 26 at 6:06 PM

$AVTX back to ph2 results highs

0 · Reply

Trapjaw Aug. 26 at 5:55 PM

$MLTX reallocation to $AVTX ?

2 · Reply

Trapjaw Aug. 26 at 4:49 PM

$AVTX

0 · Reply

Trapjaw Aug. 26 at 4:40 PM

$AVTX

0 · Reply

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2026, 7:00 AM EDT - 2 days ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

2026-08-07T11:45:56.000Z - 4 weeks ago

Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim

2026-08-07T10:16:11.000Z - 4 weeks ago

Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright

2026-08-06T11:26:47.000Z - 4 weeks ago

Avalo Therapeutics reports Q2 EPS (83c), consensus (62c)

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Avalo Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Avalo Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Avalo Therapeutics Slides: Corporate presentation

Jul 22, 2026, 7:00 AM EDT - 6 weeks ago

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

2026-07-17T20:05:11.000Z - 7 weeks ago

Avalo Therapeutics files to sell 128,189 shares of common stock for holders

Jul 17, 2026, 8:00 AM EDT - 7 weeks ago

Avalo Therapeutics Registration statement: Registration filing

Jul 7, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

2026-07-06T15:10:08.000Z - 2 months ago

Avalo Therapeutics initiated with an Outperform at Leerink

2026-06-26T11:15:39.000Z - 2 months ago

Avalo Therapeutics to join Russell 2000, Russell 3000

Jun 26, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Jun 23, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics Appoints Ron Philip to Board of Directors

2026-06-16T11:06:47.000Z - 2 months ago

Avalo Therapeutics advances AVTX-010

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics Slides: Corporate presentation

2026-06-12T09:51:17.000Z - 2 months ago

Avalo Therapeutics initiated with a Buy at BofA

Jun 2, 2026, 8:30 AM EDT - 3 months ago

Avalo Therapeutics Transcript: AGM 2026

May 22, 2026, 4:01 PM EDT - 3 months ago

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

2026-05-14T17:17:08.000Z - 3 months ago

Avalo Therapeutics price target lowered to $34 from $40 at Wedbush

2026-05-14T12:53:14.000Z - 3 months ago

Avalo Therapeutics price target raised to $45 from $39 at Mizuho

2026-05-14T10:17:40.000Z - 3 months ago

Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright

2026-05-14T09:50:09.000Z - 3 months ago

Avalo Therapeutics price target lowered to $55 from $62 at Citizens

2026-05-13T13:05:49.000Z - 3 months ago

Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Quarterly report: Q1 2026

2026-05-11T13:21:41.000Z - 3 months ago

Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler

2026-05-07T10:13:59.000Z - 4 months ago

Avalo Therapeutics price target raised to $62 from $52 at Citizens

2026-05-07T08:32:34.000Z - 4 months ago

Avalo Therapeutics 19.73M share Spot Secondary priced at $17.75

2026-05-07T07:56:17.000Z - 4 months ago

Avalo Therapeutics price target raised to $58 from $40 at BTIG

2026-05-06T13:03:49.000Z - 4 months ago

Why Is Avalo Therapeutics Stock (AVTX) Up Today?

May 5, 2026, 11:33 PM EDT - 4 months ago

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

May 5, 2026, 4:05 PM EDT - 4 months ago

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 5, 2026, 4:01 PM EDT - 4 months ago

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

May 5, 2026, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Slides: Corporate presentation

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Avalo Therapeutics Purchases Optional Milestone Buyout

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Avalo Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Avalo Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Annual report: Q4 2025

Mar 20, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Slides: Corporate presentation

Mar 10, 2026, 4:20 PM EDT - 5 months ago

Avalo Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 9:50 AM EST - 6 months ago

Avalo Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 10:00 AM EST - 6 months ago

Avalo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:00 AM EST - 6 months ago

Avalo Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 8, 2026, 7:00 AM EST - 8 months ago

Avalo Therapeutics Registration statement: Registration Filing

Dec 2, 2025, 10:30 AM EST - 9 months ago

Avalo Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 30, 2025, 6:00 PM EST - 9 months ago

Avalo Therapeutics Slides: Investor Presentation

Nov 13, 2025, 9:00 AM EST - 9 months ago

Avalo Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 2:40 PM EST - 9 months ago

Avalo Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 4:00 PM EST - 9 months ago

Avalo Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 6:00 PM EST - 10 months ago

Avalo Therapeutics Slides: Corporate Presentation

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Sep 22, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Sep 15, 2025, 11:00 AM EDT - 11 months ago

Avalo Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 9, 2025, 2:30 PM EDT - 12 months ago

Avalo Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Avalo Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Jun 30, 2025, 11:00 AM EDT - 1 year ago

Avalo Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Jun 19, 2025, 2:00 AM EDT - 1 year ago

Avalo Therapeutics Slides: Corporate Presentation

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Avalo Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Quarterly report: Q1 2025

May 8, 2025, 3:00 PM EDT - 1 year ago

Avalo Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Avalo Therapeutics Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Avalo Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Avalo Therapeutics Annual report: Q4 2024

Mar 3, 2025, 3:10 PM EST - 1 year ago

Avalo Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 11, 2025, 10:00 AM EST - 1 year ago

Avalo Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 11, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Slides: Corporate Presentation

Jan 2, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 6, 2024, 6:00 PM EST - 1 year ago

Avalo Therapeutics Quarterly report: Q3 2024

Oct 8, 2024, 7:00 AM EDT - 1 year ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Slides: Corporate Presentation

Aug 11, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Earnings release: Q2 2024

Aug 11, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Quarterly report: Q2 2024

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

Jul 16, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 11, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 24, 2024, 4:01 PM EDT - 2 years ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024, 7:30 AM EDT - 2 years ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

May 13, 2024, 7:30 AM EDT - 2 years ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

May 12, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Earnings release: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Quarterly report: Q1 2024

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 1, 2024, 6:02 AM EDT - 2 years ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Mar 29, 2024, 4:01 PM EDT - 2 years ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 28, 2024, 7:00 PM EDT - 2 years ago

Avalo Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Nov 9, 2023, 7:00 AM EST - 2 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 6:00 PM EST - 2 years ago

Avalo Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Avalo Therapeutics Quarterly report: Q3 2023

Oct 31, 2023, 7:00 AM EDT - 2 years ago

Avalo Completes Divestiture of AVTX-800 Series

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Oct 5, 2023, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 2:10 AM EDT - 2 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 12, 2023, 7:00 AM EDT - 2 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 6, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 2, 2023, 6:00 PM EDT - 3 years ago

Avalo Therapeutics Earnings release: Q2 2023

Aug 2, 2023, 6:00 PM EDT - 3 years ago

Avalo Therapeutics Quarterly report: Q2 2023

Jul 6, 2023, 4:01 PM EDT - 3 years ago

Avalo to Participate in SVB Securities Therapeutics Forum

Trapjaw Sep. 4 at 7:53 PM

$AVTX

0 · Reply

Trapjaw Sep. 2 at 12:39 PM

$AVTX low volume last days. Time for next run to 22

0 · Reply

Quantumup Sep. 1 at 12:10 PM

1 · Reply

FrostyOrbit Aug. 30 at 10:05 PM

$AVTX Cash: $472M, with runway expected into 2029.zz.

0 · Reply

Trapjaw Aug. 26 at 8:01 PM

$AVTX no sell off

0 · Reply

CaptainCoin3 Aug. 26 at 6:35 PM

$AVTX get ready for takeoff

0 · Reply

Trapjaw Aug. 26 at 6:06 PM

$AVTX back to ph2 results highs

0 · Reply

Trapjaw Aug. 26 at 5:55 PM

$MLTX reallocation to $AVTX ?

2 · Reply

Trapjaw Aug. 26 at 4:49 PM

$AVTX

0 · Reply

Trapjaw Aug. 26 at 4:40 PM

$AVTX

0 · Reply

Trapjaw Aug. 26 at 3:31 PM

$AVTX

0 · Reply

Trapjaw Aug. 26 at 3:26 PM

$AVTX

0 · Reply

Trapjaw Aug. 26 at 3:24 PM

$AVTX

0 · Reply

Doozio Aug. 26 at 3:58 AM

$AVTX ENTA 🐒🍌🧠⏰♾️

0 · Reply

Trapjaw Aug. 25 at 8:03 PM

$AVTX

0 · Reply

Trapjaw Aug. 25 at 1:51 PM

$AVTX

0 · Reply

Trapjaw Aug. 21 at 10:29 AM

$AVTX https://www.gurufocus.com/news/9046768/deep-track-capital-lp-expands-avalo-therapeutics-inc-avtx-stake-shares-look-significantly-overvalued-on-gf-value?utm_source=marketwatch&utm_medium=syndication&utm_campaign=headlines&r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news

0 · Reply

Trapjaw Aug. 21 at 9:28 AM

$AVTX

0 · Reply

Trident1014 Aug. 20 at 10:18 PM

$AVTX I've been waiting on this for 3 years. It finally shows support at $20 and the Ahole CEO sells $1.5M worth of stock like a dipshit

1 · Reply

Trapjaw Aug. 19 at 8:02 PM

$AVTX

0 · Reply

Trapjaw Aug. 19 at 2:18 PM

$MRNA $AVTX

0 · Reply

Doozio Aug. 19 at 12:42 AM

$AVTX this is the ole CERC? Out of the tightness. Faatch 💣 or….

0 · Reply

Market Cap	1.03B
Revenue (ttm)	60,000.00
Net Income (ttm)	-78.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-130,433.34%
Debt to Equity Ratio	0.00

Volume	633,200
Avg Vol	1,083,192
Day's Range	N/A - N/A
Shares Out	53.63M
Stochastic %K	23%
Beta	0.78
Analysts	Strong Sell
Price Target	$44.15